logo

Clinical Trial Results

Share

uscoronavirus apri13 03jul20 Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial.

Pfizer Inc. (PFE) and BioNTech SE (BNTX) said their investigational Covid-19 vaccine developed neutralizing antibodies in healthy patients, while causing low grade fever after the second dose.

pills jun13 22jun20 Anti-malaria drug Hydroxychloroquine may not benefit hospitalized patients with coronavirus (COVID-19), according to clinical trial conducted by the National Institutes of Health (NIH). The NIH stopped the clinical trial after its data and safety monitoring board (DSMB) determined that while there was no harm, Hydroxychloroquine provides no benefit.

AbbVie (ABBV) said that Rinvoq or upadacitinib monotherapy shows improvement in skin clearance and itch in first phase 3 study for atopic dermatitis. The results from a Phase 3 study evaluating Rinvoq in moderate to severe atopic dermatitis in adults and adolescents showed both doses of upadacitinib...

Eli Lilly and Company (LLY) said the results from a pre-planned interim analysis of the Phase 3 monarchE study of Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free survival, significantly decreasing the risk of breast...

Takeda Pharmaceutical Co. Ltd. (TAK, TKPYY.PK) announced Monday a scientific update from the AHEAD real-world study investigating the long-term outcomes associated with ADVATE [antihemophilic factor (recombinant), rAHF] in patients with hemophilia A. ADVATE is a full-length recombinant FVIII product...

Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) announced Monday new long-term plaque psoriasis data for TREMFYA (guselkumab). The company noted that the first-in-class treatment showed consistent, high levels of skin clearance through four years in adult patients with moderate to severe...

Biogen Inc. (BIIB) said the NURTURE study in pre-symptomatic patients with spinal muscular atrophy showed that early and sustained treatment with SPINRAZA for up to 4.8 years enabled unprecedented survival in infants genetically diagnosed with SMA. After up to 4.8 years of continuous treatment with SPINRAZA,...

Pfizer Inc. (PFE) announced Wednesday positive top-line results from the Phase 3 JADE TEEN trial of Abrocitinib in adolescents with moderate-to-severe atopic dermatitis (AD). Both doses of abrocitinib met the co-primary endpoints and were generally well tolerated. Abrocitinib is an investigational...

Swiss drug major Novartis (NVS) announced Friday that its Phase IIIb ARGON study met primary endpoint in a comparison of Enerzair Breezhaler (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma. The results show that once-daily treatment with single inhaler,...

Follow RTT